Eradicating mesothelin-positive human gastric and pancreatic tumors in xenograft models with optimized anti-mesothelin antibody–drug conjugates from synthetic antibody libraries

Eradicating mesothelin-positive human gastric and pancreatic tumors in xenograft models with optimized anti-mesothelin antibody–drug conjugates from synthetic antibody libraries

Abstract Mesothelin (MSLN) is an attractive candidate of targeted therapy for several cancers, and hence there are increasing needs to develop MSLN-targeting strategies for cancer therapeutics. Antibody–drug conjugates (ADCs) targeting MSLN have been demonstrated to be a viable strategy in treating...

Full description

Bibliographic Details
Main Authors: Hung-Ju Hsu, Chao-Ping Tung, Chung-Ming Yu, Chi-Yung Chen, Hong-Sen Chen, Yu-Chuan Huang, Pei-Hsun Tsai, Su-I Lin, Hung-Pin Peng, Yi-Kai Chiu, Yueh-Liang Tsou, Wei-Ying Kuo, Jhih-Wei Jian, Fei-Hung Hung, Chiao-Yun Hsieh, Michael Hsiao, Simon Shih-Hsien Chuang, Chia-Ning Shen, Yong Alison Wang, An-Suei Yang
Format: Article
Language:English
Published: Nature Publishing Group 2021-07-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-94902-1

Internet

https://doi.org/10.1038/s41598-021-94902-1

Similar Items